Cargando…
KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy
BACKGROUND: This study was carried out to evaluate the prognostic value of KIBRA in breast cancer. METHODS: This retrospective study included breast cancer patients who sought the services of the immunohistochemistry laboratory of our unit from 2006 to 2015. Tissue microarrays were constructed and i...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968668/ https://www.ncbi.nlm.nih.gov/pubmed/29793439 http://dx.doi.org/10.1186/s12885-018-4491-6 |
_version_ | 1783325816128536576 |
---|---|
author | Mudduwa, Lakmini Peiris, Harshini Gunasekara, Shania Abeysiriwardhana, Deepthika Liyanage, Nimsha Rayala, Suresh K. Liyanage, Thusharie |
author_facet | Mudduwa, Lakmini Peiris, Harshini Gunasekara, Shania Abeysiriwardhana, Deepthika Liyanage, Nimsha Rayala, Suresh K. Liyanage, Thusharie |
author_sort | Mudduwa, Lakmini |
collection | PubMed |
description | BACKGROUND: This study was carried out to evaluate the prognostic value of KIBRA in breast cancer. METHODS: This retrospective study included breast cancer patients who sought the services of the immunohistochemistry laboratory of our unit from 2006 to 2015. Tissue microarrays were constructed and immunohistochemical staining was done to assess the KIBRA expression. The Kaplan-Meier model for univariate and Cox-regression model with backward stepwise factor retention method for multivariate analyses were used. Chi square test was used to find out the associations with the established prognostic features. RESULTS: A total of 1124 patients were included in the study and KIBRA staining of 909 breast cancers were available for analysis. Cytoplasmic KIBRA expression was seen in 39.5% and nuclear expression in 44.8%. Overall KIBRA–low breast cancers accounted for 41.5%. KIBRA nuclear expression was significantly associated with positive ER and PR expression. Luminal breast cancer patients who had endocrine therapy and KIBRA-low expression had a RFS disadvantage over those who were positive for KIBRA (p = 0.02). Similarly, patients who received chemotherapy and had overall KIBRA-low expression also demonstrated a RFS disadvantage compared to those who had overall positive KIBRA expression (p = 0.018). This effect of KIBRA was independent of the other factors considered for the model. CONCLUSION: Overall low-KIBRA expression has an independent effect on the RFS and predicts the RFS outcome of luminal breast cancer patients who received endocrine therapy and breast cancer patients who received chemotherapy. |
format | Online Article Text |
id | pubmed-5968668 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59686682018-05-30 KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy Mudduwa, Lakmini Peiris, Harshini Gunasekara, Shania Abeysiriwardhana, Deepthika Liyanage, Nimsha Rayala, Suresh K. Liyanage, Thusharie BMC Cancer Research Article BACKGROUND: This study was carried out to evaluate the prognostic value of KIBRA in breast cancer. METHODS: This retrospective study included breast cancer patients who sought the services of the immunohistochemistry laboratory of our unit from 2006 to 2015. Tissue microarrays were constructed and immunohistochemical staining was done to assess the KIBRA expression. The Kaplan-Meier model for univariate and Cox-regression model with backward stepwise factor retention method for multivariate analyses were used. Chi square test was used to find out the associations with the established prognostic features. RESULTS: A total of 1124 patients were included in the study and KIBRA staining of 909 breast cancers were available for analysis. Cytoplasmic KIBRA expression was seen in 39.5% and nuclear expression in 44.8%. Overall KIBRA–low breast cancers accounted for 41.5%. KIBRA nuclear expression was significantly associated with positive ER and PR expression. Luminal breast cancer patients who had endocrine therapy and KIBRA-low expression had a RFS disadvantage over those who were positive for KIBRA (p = 0.02). Similarly, patients who received chemotherapy and had overall KIBRA-low expression also demonstrated a RFS disadvantage compared to those who had overall positive KIBRA expression (p = 0.018). This effect of KIBRA was independent of the other factors considered for the model. CONCLUSION: Overall low-KIBRA expression has an independent effect on the RFS and predicts the RFS outcome of luminal breast cancer patients who received endocrine therapy and breast cancer patients who received chemotherapy. BioMed Central 2018-05-24 /pmc/articles/PMC5968668/ /pubmed/29793439 http://dx.doi.org/10.1186/s12885-018-4491-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Mudduwa, Lakmini Peiris, Harshini Gunasekara, Shania Abeysiriwardhana, Deepthika Liyanage, Nimsha Rayala, Suresh K. Liyanage, Thusharie KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy |
title | KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy |
title_full | KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy |
title_fullStr | KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy |
title_full_unstemmed | KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy |
title_short | KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy |
title_sort | kibra; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968668/ https://www.ncbi.nlm.nih.gov/pubmed/29793439 http://dx.doi.org/10.1186/s12885-018-4491-6 |
work_keys_str_mv | AT mudduwalakmini kibraanovelbiomarkerpredictingrecurrencefreesurvivalofbreastcancerpatientsreceivingadjuvanttherapy AT peirisharshini kibraanovelbiomarkerpredictingrecurrencefreesurvivalofbreastcancerpatientsreceivingadjuvanttherapy AT gunasekarashania kibraanovelbiomarkerpredictingrecurrencefreesurvivalofbreastcancerpatientsreceivingadjuvanttherapy AT abeysiriwardhanadeepthika kibraanovelbiomarkerpredictingrecurrencefreesurvivalofbreastcancerpatientsreceivingadjuvanttherapy AT liyanagenimsha kibraanovelbiomarkerpredictingrecurrencefreesurvivalofbreastcancerpatientsreceivingadjuvanttherapy AT rayalasureshk kibraanovelbiomarkerpredictingrecurrencefreesurvivalofbreastcancerpatientsreceivingadjuvanttherapy AT liyanagethusharie kibraanovelbiomarkerpredictingrecurrencefreesurvivalofbreastcancerpatientsreceivingadjuvanttherapy |